The present study was designed to investigate the role of a protein kinase C (PKC) isoform in the uncoupling of the -opioid receptor from G-proteins after repeated intrathecal injection of a selective -receptor agonist, [D-Ala 
The opioid agonists modulate a number of physiological processes including pain, reward, stress, and immune responses via the stimulation of various opioid receptors (Mansour et al., 1988) . One of the major opioid receptor types, the -opioid receptor, was cloned in 1993 and classified as a G-protein-coupled receptor . Opioids mainly inhibit cyclic AMP formation, close voltage-sensitive Ca 2ϩ channels, and open K ϩ channels via the stimulation of G i /o proteins (Childers, 1991) . Over the past few years opioids, including -opioids, also have been shown to activate the phosphoinositide-signaling cascade in a variety of cells and neural tissues (Chen and Huang, 1991; Mangoura and Dawson, 1993; Smart et al., 1995; Ueda et al., 1995) .
The receptor-coupled hydrolysis of membranal phosphoinositides, particularly phosphatidyl inositol 4,5-bisphosphate (PIP 2 ), yields two intracellular second messengers, diacylglycerol (DAG) and inositol triphosphate (IP 3 ). DAG activates protein kinase C (PKC), and IP 3 mobilizes Ca 2ϩ after binding with cytoplasmic IP 3 receptors (Berridge, 1987; Fisher et al., 1992 Fisher et al., , 1993 . These processes appear to be an important part of the signal transduction mechanism for controlling the various cellular events in the CNS.
PKC is a key regulatory enzyme that modulates both presynaptic and postsynaptic neuronal function, synthesis and release of neurotransmitters, and the regulation of receptors. PKC has expanded into a family of closely related protein, which can be subdivided and classified on the basis of certain structural and biochemical similarities. Several PKC isoforms, especially conventional PKCs (cPKCs) including ␣, ␤I, ␤II, and ␥ that are Ca 2ϩ -dependent and activated by both phosphatidylserine (PtdSer) and DAG, have been identified in neurons of the spinal cord; in each case immunocytochemistry has shown that they are concentrated in the superficial laminae of the dorsal horn (Malmberg et al., 1997; Martin et al., 1999) .
We previously reported that activation of PKC in the spinal cord is implicated in the development of spinal antinociceptive tolerance to -opioid receptor agonists in mice (Narita et al., 1995) . The -opioid receptor contains several potential phosphorylation sites Kaufman et al., 1995) . It has been hypothesized that activated PKC directly phosphorylates the opioid receptor and subsequently induces the uncoupling of opioid receptors from G-proteins (Pei et al., 1995) . However, there is little or no direct evidence to support the contention that repeated stimulation of -opioid receptors by opioid -agonists produces the PKC-dependent uncoupling of -opioid receptors from G-proteins. In the present study we therefore investigated whether repeated intrathecal injection of a highly selective 
MATERIALS AND METHODS
Animals. Male CD-1 mice (Charles River Breeding Laboratories, Wilmington, M A) and PKC␥ knock-out mice (The Jackson Laboratory, Bar Harbor, M A), which were maintained on C57BL /6 and 129Sv mixed genetic backgrounds as described previously (Abeliovich et al., 1993) , were used. Animals were housed five per cage in a room maintained at 22 Ϯ 0.5°C with an alternating 12 hr light /dark cycle.
[ 35 S]GTP␥S binding assay buffer containing (in mM) 50 Tris-HC l, pH 7.4, 5 MgC l 2 , 1 EGTA, and 100 NaC l and recentrif uged at 48,000 ϫ g at 4°C for 10 min. The final pellets were resuspended in assay buffer as membranous fractions for the [ 35 S]GTP␥S binding. The reaction was initiated by the addition of membrane suspension (3-8 g of protein for each assay as determined by the method of Bradford, 1976) into the assay buffer with the opioid receptor agonists, 30 M guanosine-5Ј-diphosphate (GDP), and 50 pM [
35 S]GTP␥S (1000 C i /mmol; Amersham, Arlington Heights, IL). The suspensions were incubated at 25°C for 2 hr, and the reaction was terminated by filtering through Whatman GF/ B glass filters, which had been soaked previously in a soaking buffer of 50 mM Tris-HC l, pH 7.4, and 5 mM MgC l 2 at 4°C for 2 hr, using a Brandel cell harvester (model M-24; Brandel, Gaithersburg, MD). Then the filters were washed three times with 5 ml of an ice-cold Tris-HC l buffer, pH 7.4, and transferred to scintillation counting vials containing scintillation cocktail, 0.5 ml of Soluene-350 (Packard Instrument, Meriden, C T), and 4 ml of Hionic Fluor (Packard Instrument). The radioactivity in the samples was determined with a liquid scintillation analyzer (model 1600CA, Packard Instrument). Nonspecific binding was measured in the presence of 10 M unlabeled GTP␥S.
Western blotting. The spinal cord was removed quickly after decapitation of mice and homogenized in ice-cold buffer A containing (in mM) 20 Tris-HC l, pH 7.5, 2 EDTA, 0.5 EGTA, and 1 phenylmethylsulfonyl fluoride plus 25 g /ml leupeptin, 0.1 mg /ml aprotinin, and 0.32 M sucrose. The homogenate was centrif uged at 1,000 ϫ g for 10 min, and the supernatant was ultracentrif uged at 100,000 ϫ g for 30 min at 4°C. The resulting supernatant was retained as the cytosolic fraction. The pellets were washed with buffer B (buffer A without sucrose) and homogenated in buffer B with 1% Triton X-100. After incubation for 45 min, soluble fractions were obtained by ultracentrif ugation at 100,000 ϫ g for 30 min and then were retained as membranous fractions for Western blotting. An aliquot of tissue sample was diluted with an equal volume of 2ϫ electrophoresis sample buffer (Protein Gel L oading Dye-2X, Amresco, Solon, OH) containing 2% SDS and 10% glycerol with 0.2 M dithiothreitol. Proteins (5-20 g / lane as determined by the method of Bradford, 1976) were separated by size on 4 -20% SDS-polyacrylamide gradient gel by using the buffer system of Laemmli (1970) and were transferred to nitrocellulose membranes in Tris-glycine buffer containing 25 mM Tris and 192 mM glycine. For immunoblot detection of PKC isozymes the membranes were blocked in Tris-buffered saline (TBS) containing 5% nonfat dried milk (Bio-Rad Laboratories, Hercules, CA) for 1 hr more at room temperature with agitation. The membrane was incubated with primary antibody diluted in TBS [PKC␣, PKC␤I, PKC␤II, and PKC␥ at ratios of 1:4000 (␣), 1:3000 (␤I and ␤II), 1:1000 (␥); Santa Cruz Biotechnology, Santa Cruz, CA] containing 5% nonfat dried milk overnight at 4°C. Then the membrane was washed twice for 5 min and twice for 10 min in Triton X-TBS (TTBS) containing TBS and 0.05% Triton X-100, followed by 2 hr of incubation at room temperature with horseradish peroxidase-conjugated goat anti-rabbit IgG (Southern Biotechnology Associates, Birmingham, AL) diluted 1:10,000 in TBS containing 5% nonfat dried milk. After this incubation the membranes were washed twice for 5 min and then three times for 10 min in TTBS. The antigen -antibody peroxidase complex was detected finally by enhanced chemiluminescence (Pierce, Rockford, IL) according to the manufacturer's instructions and visualized by exposure to Amersham Hyperfilm (Amersham Life Sciences, Arlington Heights, IL).
Intrathecal injection.
Intrathecal administration was performed by following the method described by Hylden and Wilcox (1980) , using a 25 l Hamilton syringe with a 30 gauge needle. Injection volumes were 5 l for intrathecal injection. Statistical anal ysis. The data are expressed as the mean Ϯ SEM. The statistical significance of differences between the groups was assessed with a one-way ANOVA, followed by Dunnett's test (comparison with a control group) or Newman -Keuls test (comparisons between multiple groups).
RESULTS

Effects of chronic intrathecal treatment with DAMGO on increases of the [ 35 S]GTP␥S binding induced by -, ␦-, and -opioid agonists in the spinal cord
Under these conditions groups of mice were injected intrathecally with saline (5 l/mouse) or DAMGO (50 ng/mouse) once a day for 1-7 d. At 24 hr after the last injection of each group the spinal cord membranes were prepared for each assay. As shown in Table  1 , the -opioid receptor agonists DAMGO, endomorphin-1, and endomorphin-2, each at 10 M, produced marked increases in 
3.5 Ϯ 2.7* 10 M U-69,593 (-agonist) 16.1 Ϯ 2.0 10 M U-69,593 ϩ 0.1 M nor-BNI Ϫ0.6 Ϯ 3.5* (Table 1) , These effects were blocked completely by coincubation with the specific ␦-opioid receptor antagonist N TI ( (Fig. 4) 35 S]GTP␥S binding in mice treated with saline and DAMGO for 5 d was 29.2 Ϯ 1.2 and 28.6 Ϯ 1.3 fmol/mg protein, respectively. The statistical significance of differences between the groups was assessed with a one-way ANOVA, followed by Dunnett's test. *p Ͻ 0.05 versus saline-treated group. F values of one-way ANOVA in 10 M endomorphin-1, 0.1 M endomorphin-2, and 10 M endomorphin-2 are F (1,13) ϭ 9.135, F (1,4) ϭ 9.351, and F (1,10) ϭ 14.037, respectively.
intrathecally with DAMGO in the absence or presence of a specific PKC inhibitor, Ro-32-0432 (250 ng/mouse). As shown in eFigure 5, treatment of Ro-32-0432 coadministered with DAMGO completely blocked the decrease of the DAMGOstimulated [
35 S]GTP␥S binding induced by repeated DAMGO injection for 5 d. Treatment with Ro-32-0432 alone had no effect on the DAMGO-stimulated [
35 S]GTP␥S binding (Fig. 5) .
Identification of cPKC isoforms involved in -opioid receptor desensitization induced by chronic treatment with DAMGO
The levels of cPKC isoforms in membranes of the spinal cord after the repeated injection of DAMGO were analyzed quantitatively by Western blot analysis. Groups of mice were treated intrathecally with DAMGO (50 ng/mouse) or saline for 5 d; on day 6 spinal cord membranes were prepared for the assay. Immunoreactivity of the PKC␥ isoform was enhanced significantly by DAMGO treatment as compared with that of saline treatment, whereas the other three cPKC isoforms, PKC␣, PKC␤I, and PKC␤II, were not altered (Fig. 6 A,B) .
Lack of -opioid receptor desensitization induced by chronic treatment with DAMGO in PKC␥ knock-out mice
To investigate further the role of the PKC␥ isoform in the process of chronic DAMGO-induced desensitization, we next investigated whether repeated intrathecal injections of DAMGO caused no effect on the DAMGO-stimulated [ 35 S]GTP␥S binding in mice lacking the PKC␥ isoform. Immunoblot analysis showed that no PKC␥ protein could be detected in both membranous and cytosolic fractions of the spinal cord obtained from PKC␥ knockout mice (Fig. 7A) . Immunoreactivities of the other three cPKC isoforms, PKC␣, PKC␤I, and PKC␤II, in mice lacking the PKC␥ 35 S]GTP␥S binding in mice treated with saline and DAMGO for 5 d was 29.2 Ϯ 1.2 and 28.6 Ϯ 1.3 fmol/mg protein, respectively. The statistical significance of differences between the groups was assessed with a one-way ANOVA, followed by Dunnett's test. Figure 6 . The levels of cPKC isoforms in spinal cord membranes after repeated intrathecal injections of DAMGO. Groups of mice were injected intrathecally with saline (5 l/mouse) or DAMGO (50 ng/mouse) once a day for 5 d. At 24 hr after the last injection the spinal cord membranes were prepared for immunoblotting. A, Representative Western blot of PKC␣, PKC␤I, PKC␤II, and PKC␥ isoform proteins. B, Changes in the membrane-located protein levels of cPKC isoforms in spinal cord membranes after repeated intrathecal injections of DAMGO. Each column represents the mean Ϯ SEM for four samples. The statistical significance of differences between the groups was assessed with a one-way ANOVA, followed by Dunnett's test. *p Ͻ 0.05 versus saline-treated group. The F value of one-way ANOVA in the PKC␥ isoform is F (1,6) ϭ 46.531.
isoform were detectable to the same degree as the wild type (data not shown), confirming the specificity of these mutant mice. As shown in Figure 7B , repeated intrathecal treatment with DAMGO once a day for 7 d consecutively produced a 20.0% reduction in the [
35 S]GTP␥S binding stimulated by DAMGO at 10 M to spinal membranes of wild-type mice ( p Ͻ 0.05 vs saline pretreatment). However, the same chronic treatment with DAMGO did not affect significantly the increases of the DAMGO-stimulated [ 35 S]GTP␥S binding in mice lacking the PKC␥ isoform (Fig. 7C) .
DISCUSSION
Chronic daily intrathecal DAMGO treatment attenuates the increases of [
35 S]GTP␥S bindings stimulated by -opioid, but not ␦-or -opioid, agonists in the mouse spinal cord
We found in the present study that mice repeatedly intrathecally injected with a selective -opioid receptor agonist DAMGO showed the time-dependent desensitization of a -opioidergic system to activate G-proteins in the spinal cord. This desensitization was selective to -, but not to ␦-and -, opioidergic systems to activate G-proteins. These results indicate that chronic intrathecal injection of -opioids uncouples the spinal -opioid receptor from G-proteins, resulting in the desensitization of a -opioidergic system in the mouse spinal cord.
PKC in the spinal cord is involved in -opioid receptor desensitization induced by chronic treatment with DAMGO
Tolerance to opioid analgesia is a major drawback in clinical use of these analgesics. It has been proposed that chronic adaptive molecular mechanisms in opioid tolerance involve some protein kinases, including protein kinase A (PKA), PKC, and G-proteincoupled receptor kinase. We have reported previously that intrathecal pretreatment with a membrane-permeable PKC inhibitor, calphostin C, but not with a specific PKA inhibitor, blocks the development of the antinociceptive tolerance to intrathecally administered DAMGO in mice (Narita et al., 1995) . We also found that the activation of PKC by phorbol esters attenuates either the opioid-induced antinociceptive effect or the G-protein activation (Narita et al., 1996 (Narita et al., , 1997 . These findings indicate that activated PKC is involved in the process of the development of opioid tolerance.
Treatment of a specific PKC inhibitor Ro-32-0432 coadministered with DAMGO into the spinal cord completely blocked the desensitization of spinal -opioidergic systems induced by chronic DAMGO treatment. Considering that the activation of PKC induces the phosphorylation of several membrane proteins, the receptor itself seems to be one of the good targets. Indeed, the opioid receptors can be phosphorylated by PKC (Pei et al., 1995) . It is therefore most likely that the activation of PKC by chronic treatment with -opioids may lead to the phosphorylation of membrane-bound -opioid receptors and in turn causes the uncoupling of -opioid receptors from G-proteins after chronic treatment with -opioids in the spinal cord.
Identification of the PKC␥ isoform involved in -opioid receptor desensitization induced by chronic treatment with DAMGO
Recent cloning studies revealed that the PKC family consists of at least 12 isoforms possessing distinct differences in structure, substrate requirement, expression, and localization that therefore may underlie diverse physiological functions (Way et al., 2000) . In the present study we thus examined whether repeated intrathecal administration of DAMGO for 5 d could alter the levels of membrane-bound PKC isoforms, especially cPKCs, in the mouse spinal cord. In spinal cord membranes obtained from mice injected repeatedly with DAMGO for 5 d, the upregulation of the 35 S]GTP␥S binding to spinal cord membranes from wild-type mice. Groups of wildtype mice were injected intrathecally with saline (5 l/mouse) or DAMGO (50 ng/mouse) once a day for 7 d. At 24 hr after the last injection the spinal cord membranes were prepared for each assay. The assay was conducted with or without DAMGO (0.1-10 M). Data represent the mean Ϯ SEM for 11 independent samples. The basal [
35 S]GTP␥S binding in wild-type mice treated with saline and DAMGO for 7 d was 31.1 Ϯ 2.8 and 27.5 Ϯ 1.2 fmol/mg protein, respectively. The statistical significance of differences between the groups was assessed with a oneway ANOVA, followed by Dunnett's test. *p Ͻ 0.05 versus saline-treated group. F values of one-way ANOVA in 0.1, 1, and 10 M DAMGO are F (1,20) ϭ 5.954, F (1,20) ϭ 10.640, and F (1,20) ϭ 8.244, respectively. C, No development of the -opioid receptor-mediated downregulation by repeated DAMGO injection in mice lacking the PKC␥ isoform. Groups of PKC␥ knock-out mice were injected intrathecally with saline (5 ml/ mouse) or DAMGO (50 ng/mouse) once a day for 7 d. At 24 hr after the last injection the spinal cord membranes were prepared for each assay. The assay was conducted with or without DAMGO (0.1-10 M). Data represent the mean Ϯ SEM for 11 independent samples. The basal [
35 S]GTP␥S binding in PKC␥ knock-out mice treated with saline and DAMGO for 7 d was 26.7 Ϯ 2.1 and 29.1 Ϯ 3.2 fmol/mg protein, respectively. The statistical significance of differences between the groups was assessed with a one-way ANOVA, followed by Dunnett's test.
PKC␥ isoform in the spinal cord was clearly noted. Three other cPKC isoforms, PKC␣, PKC␤I, and PKC␤II, were not altered significantly after repeated administration of DAMGO. The results are consistent with the previous finding that chronic spinal administration of morphine caused a significant increase in levels of PKC␥ in spinal cord membranes of rats . These data raise the possibility that the PKC␥ isoform dominantly modulates an autoinhibition of spinal -opioidergic systems.
The PKC␥ isoform has been identified in neurons of the brain and spinal cord. A recent study in mice lacking the PKC␥ isoform has shown that the PKC␥ isoform may be critical for synaptic plasticity such as neuropathic pain (Malmberg et al., 1997) . The neuropathic pain after partial nerve ligation results in a somatotopically organized upregulation of PKC␥ in the superficial dorsal horn and its translocation from the cytoplasm and nucleus toward the plasma membrane of immunoreactive neurons . The present study with PKC␥ knock-out mice revealed that repeated spinal administration of -agonist in mice lacking the PKC␥ isoform gene failed to cause any desensitization of G-protein activation by the -agonist. Taking together with the present results of the immunoblotting, the PKC␥ isoform is likely to be one of the most important factors to modulate the homologous desensitization of spinal -opioidergic systems. Recent studies with dual immunofluorescence labeling showed that PKC␥ was present in only 5% of cells expressing -opioid receptors in rat spinal cord (Polgar et al., 1999) . If this is also the case in the mouse, one wonders how -opioid receptors in the spinal cord could be phosphorylated directly by PKC␥. The results obtained from this study would suggest the possibility that chronic treatment with DAMGO may cause an increase of the expression of PKC␥ in -opioid receptor-containing cells.
Because it has been well recognized that there is no crosstolerance to opioid-induced analgesia/antinociception among opioid receptor types, the lack of cross-talk between -and ␦-or -opioidergic systems on the desensitization of opioid-induced G-protein activation after repeated treatment with -agonists was expected. However, it should be pointed out that either ␦-or -opioid receptors possess the phosphorylation sites for PKC (Mollereau et al., 1994; Yasuda et al., 1998) . Although the exact mechanism is unclear at this time, it is possible that the remaining PKC isoforms activated by chronic treatment with a ␦-or -opioid receptor agonist provide sufficient kinase activity to regulate ␦-and -opioidergic systems.
In conclusion, the present results indicate a potential role for PKC, especially the PKC␥ isoform, in the process of uncoupling of the spinal -opioid receptor from G-proteins in mice chronically treated intrathecally with a specific -opioid receptor agonist, DAMGO. We propose that PKC␥ may be activated after the repeated administration of -opioids and may play an important role in the development of -opioid receptor-mediated tolerance.
